Every material Form 8-K Moderna filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Moderna entered a $1.5 billion Credit and Guaranty Agreement dated November 19, 2025, with Ares Capital Corporation as administrative and collateral agent. The company borrows $600 million at closing, with $900 million more available as delayed draw term loans, and the loans mature November 24, 2030. The facility carries a minimum liquidity covenant of at least $500 million in cash and cash equivalents, which rises to $750 million if more than $1 billion is drawn.
Facility totals $1.5 billion: $600 million initial term loan and $900 million in delayed draw term loans
Interest at Term SOFR plus 5.50% or base rate plus 4.50%; maturity date November 24, 2030
Loans secured by an all-asset collateral grant and guaranteed by US, Canadian, UK, Swiss and Australian subsidiaries
Weekly minimum cash covenant of $500 million, rising to $750 million if over $1 billion is drawn; covenant not tested if 30-day average market capitalization exceeds $5 billion
Moderna reported third-quarter 2025 revenue of $1.0 billion, down 45% from $1.9 billion a year earlier, mainly due to lower COVID vaccine sales, and a GAAP net loss of $200 million compared with net income of $13 million in the prior-year quarter. The company narrowed its 2025 revenue projection to $1.6 to $2.0 billion from $1.5 to $2.2 billion, while lowering expected operating expenses and raising its expected year-end cash balance, which matters to shareholders because revenue and profit fell even as cost guidance improved.
Q3 2025 revenue was $1.0 billion, down 45% from $1.9 billion; net product sales fell $847 million, or 47%
Q3 GAAP net loss was $200 million, or $(0.51) per share, versus net income of $13 million, or $0.03 per share, a year earlier
2025 revenue range narrowed to $1.6 to $2.0 billion from $1.5 to $2.2 billion
2025 year-end cash and investments projected at $6.5 to $7 billion, up from about $6 billion
Moderna reported second-quarter 2025 total revenue of $142 million, down 41% from $241 million a year earlier, and a net loss of $825 million, or $2.13 per share, versus a $3.33 loss per share a year earlier. The company lowered the high end of its 2025 revenue range by $300 million to $1.5 to $2.2 billion, mainly because some U.K. contracted deliveries shifted into the first quarter of 2026, while it expects operating expenses to improve by about $400 million.
Q2 2025 total revenue was $142 million, down 41% from $241 million; Q2 net loss was $825 million, versus $1.3 billion a year earlier
2025 revenue range is now $1.5 to $2.2 billion, a $300 million reduction at the high end
2025 GAAP operating expenses are now expected at $5.9 to $6.1 billion, an improvement of about $400 million
Year-end 2025 cash balance expected at about $6 billion; cash and investments were $7.5 billion as of June 30, 2025
Moderna reported first-quarter 2025 revenue of $108 million, down from $167 million a year earlier, while its net loss narrowed to $971 million from $1,175 million. The company reiterated its 2025 revenue range of $1.5 to $2.5 billion and said it expects estimated GAAP operating costs to fall by $1.4 to $1.7 billion by 2027 compared with its 2025 estimate. For shareholders, the lower revenue and cash balance contrast with the smaller loss and planned cost reductions.
Total revenue was $108 million in Q1 2025 versus $167 million in Q1 2024; net product sales were $86 million.
Net loss was $971 million, or $(2.52) per share, compared with $1,175 million, or $(3.07) per share, a year earlier.
The 2025 revenue outlook of $1.5 to $2.5 billion was reiterated, with year-end cash and investments projected at about $6 billion.
Cash, cash equivalents and investments were $8.4 billion at March 31, 2025, down from $9.5 billion at December 31, 2024.
Moderna reported fourth-quarter 2024 revenue of $1.0 billion, down from $2.8 billion a year earlier, and a net loss of $1.1 billion, compared with net income of $217 million in the same quarter of 2023. For the full year, revenue fell to $3.2 billion from $6.8 billion, but the net loss narrowed to $3.6 billion from $4.7 billion, and the company reiterated its 2025 revenue range of $1.5 to $2.5 billion.
Q4 2024 net loss was $1.1 billion, or $(2.91) per share, versus Q4 2023 net income of $217 million
Q4 2024 cost of sales included a non-cash charge of $238 million tied to termination of a contract manufacturing agreement
Full-year 2024 revenue was $3.2 billion versus $6.8 billion in 2023; net loss was $3.6 billion versus $4.7 billion
2025 revenue expected at $1.5 to $2.5 billion (reiterated), with year-end 2025 cash and investments projected at approximately $6 billion
Moderna disclosed preliminary, unaudited 2024 product sales of $3.0-3.1 billion and year-end cash of about $9.5 billion, ahead of its January 13, 2025 J.P. Morgan presentation. It also set a 2025 revenue range of $1.5-2.5 billion, mostly in the second half, and projected 2025 cash cost reductions of $1.0 billion and year-end 2025 cash of about $6.0 billion. The 2024 figures remain subject to the ongoing audit, and the filing gives no prior-year comparison for the new 2025 range.
Unaudited 2024 product sales of $3.0-3.1 billion, including $1.7 billion in the U.S.
Year-end 2024 cash, cash equivalents and investments of about $9.5 billion (unaudited).
2025 revenue projected at $1.5-2.5 billion, mostly in the second half; 2025 cash cost reductions of $1.0 billion, with a further $0.5 billion planned for 2026.
Expected year-end 2025 cash and investments of about $6.0 billion; full results due February 14, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Moderna filing is on SEC EDGAR ↗. 8-K briefs of other companies →